Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III bought 9,215 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were purchased at an average price of $20.76 per share, with a total value of $191,303.40. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Xencor, Inc. (XNCR) traded up $0.52 during midday trading on Friday, reaching $21.53. The company had a trading volume of 602,278 shares, compared to its average volume of 224,380. Xencor, Inc. has a fifty-two week low of $18.55 and a fifty-two week high of $28.64.

A number of equities research analysts have recently weighed in on XNCR shares. Cantor Fitzgerald started coverage on Xencor in a research report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 target price for the company. ValuEngine downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. BidaskClub upgraded Xencor from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 7th. Zacks Investment Research upgraded Xencor from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. Finally, Canaccord Genuity set a $36.00 target price on Xencor and gave the stock a “buy” rating in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. Xencor presently has an average rating of “Hold” and an average target price of $30.80.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can increased its holdings in Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,005 shares during the last quarter. SG Americas Securities LLC increased its holdings in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 3,252 shares during the last quarter. Legal & General Group Plc increased its holdings in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 385 shares during the last quarter. Principal Financial Group Inc. bought a new stake in Xencor in the third quarter valued at about $201,000. Finally, Citadel Advisors LLC bought a new stake in Xencor in the second quarter valued at about $224,000. Institutional investors and hedge funds own 77.62% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Acquires 9,215 Shares of Stock” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/xencor-inc-xncr-major-shareholder-john-s-stafford-iii-acquires-9215-shares-of-stock/1768285.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with Analyst Ratings Network's FREE daily email newsletter.